Bausch Health Announces VYZULTA® (latanoprostene bunod ophthalmic solution), 0.024%, is Now Approved in South Korea
Canada NewsWire SOPHIA ANTIPOLIS,FranceandLAVAL, QC,Feb. 9, 2021/CNW/ — Bausch Health Companies Inc. (NYSE/TSX: BHC) (“Bausch Health” or the “Company”), Bausch
Read more